Skip to main content
SpringerLink
Log in

The EMA is recommending the authorisation of lacosamide [Vimpat] syrup for patients with epilepsy

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. EMA.European Medicines Agency recommends authorisation of Vimpat syrup for patients who cannot swallow tablets. Internet Document: [1 page], 16 Dec 2011. Available from: URL: http://www.ema.europa.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The EMA is recommending the authorisation of lacosamide [Vimpat] syrup for patients with epilepsy. React. Wkly. 1384, 3 (2012). https://doi.org/10.2165/00128415-201213840-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213840-00009

Keywords

Search

Navigation